ArticleFrontiers in oncology2020
A Prognostic Microenvironment-Related Immune Signature
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Evaluating a Glioma Transcriptomic Signature Against a Clinical Reference Model and a Random-Signature Null Distribution: A Leakage-Controlled Internal Audit and a Survey of the Field.Diagnostics (Basel, Switzerland) · 2026Article
- Complement-Targeted Therapies in Glioblastoma: A Systematic Review.Biomedicines · 2026Review
- Development and validation of a robust cuproptosis related signature for primary glioma via machine learning aided by loop training and validation.Discover oncology · 2026Article
- Biomarkers for predicting immunotherapy response and resistance in glioblastoma.Frontiers in immunology · 2026Review
- Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.Journal of advanced research · 2025Review
- An immune-related gene pair signature predicts the prognosis and immunotherapeutic response in glioblastoma.Heliyon · 2024Article
- A cuproptosis-related gene DLAT as a novel prognostic marker and its relevance to immune infiltration in low-grade gliomas.Heliyon · 2024Article
- Identification ofBiomedicines · 2024Article
- Editorial: Application of rehabilomics in surgical conditions.Frontiers in surgery · 2024Article
- Article
- Article
- A new prognostic model for glioblastoma multiforme based on coagulation-related genes.Translational cancer research · 2023Article
- Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.Cancer medicine · 2023Article
- Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival.Cancer immunology, immunotherapy : CII · 2022Article
- Glioblastoma Microenvironment and Cellular Interactions.Cancers · 2022Review
- Inflammatory aging clock: A cancer clock to characterize the patients' subtypes and predict the overall survival in glioblastoma.Frontiers in genetics · 2022Article
- HOTAIRM1 Maintained the Malignant Phenotype of tMSCs Transformed by GSCs via E2F7 by Binding to FUS.Journal of oncology · 2022Article
- An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration.Frontiers in genetics · 2022Article
- Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma.Journal of immunology research · 2022Article
- Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn the development of immunotherapies in gliomas, the tumor microenvironment (TME) needs to be investigated. We aimed to construct a prognostic microenvironment-related immune signature
methodsStromal score (SS) and immune score (IS) were calculated
resultsWe obtained 220 upregulated DEGs and 42 downregulated DEGs in both high-IS and high-SS groups. The Cox regression highlighted 155 prognostic DEGs, out of which we selected 4 genes (CD86, ANXA1, C5AR1, and CD5) to construct a PROMISE model. The model stratifies glioma patients in TCGA as well as in CGGA with distinct survival outcome (P<0.05, Hazard ratio [HR]>1) and acceptable predictive accuracy (AUCs>0.6). With the nomogram, an individualized survival chance could be predicted intuitively with specific age, tumor grade, Isocitrate dehydrogenase (IDH) status, and the PROMISE risk score. ROC showed significant discrimination with the area under curves (AUCs) of 0.917 and 0.817 in TCGA and CGGA, respectively. GSEA between risk groups in both data sets were significantly enriched in multiple immune-related pathways. The Cibersort analysis highlighted four immune cells, i.e., CD 8 T cells, neutrophils, follicular helper T (Tfh) cells, and Natural killer (NK) cells.
conclusionsThe PROMISE model can further stratify both LGG and GBM patients with distinct survival outcomes.These findings may help further our understanding of TME in gliomas and shed light on immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.